The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in patients with type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [4]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 2
- Toto RD, 2013, J Am Soc Nephrol, 24
- 10.1056/NEJMsr077003 · DOI · Paper page
Cited by
Sorted by citations
Items 601–698 of 698
Faculty Opinions recommendation of Carbotoxicity-Noxious Effects of Carbohydrates.
Kapahi, P. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734245524.793552366
Aschner, P. J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727299606.793538292
Ischemic Heart Failure: About 140 Cases
Dihi, B., Eljazouli, H., Arioua., S., Zbitou, A., Bouzerda, A., & Khatouri, A. (2022) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2022.v10i06.019
Empagliflozin as a part of optimal medical therapy for chronic heart failure
Uskach, T. M. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20221702116
Ahmed, S. F., Alghamdi, G. A., Albalawi, A. A., AlQahtani, M., Ghonim, I. M., Elhady, H. M., Abdelhamid, S. A., & Eldesouky, A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94189
Ballaji, W. K., & Hadadi, H. M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94186
Role of SGLT2 Inhibitors and GLP-1 Analogs in Cardiovascular Risk Reduction in Type 2 Diabetes
Rashed, M. H., Dauyoumor, T. D., Corney, S. M., Konono, K., Joubert, N., Mohamed, M., Sukhoo-Pertab, M., Makhomisane, M., Njeri, I., Mwita, J. C., et al. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94188
Diagnostic approach to eosinophilia in children
Shasho, R. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94190
Knowledge, Attitude and Practice of Non-Psychiatric Physicians about Addiction
Al-Ahmari, S. M., Almusa, A. A., Alshomrani, A. A., Ahmary, W. S. H. A., Assiry, Z. S. A., Alqahtany, S. M. S., Asiri, A. Y., Alqahtani, T. S., Alassiri, N. S., & Mostafa, O. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94185
Inoue, A., Katayama, A., Sue, M., Hasegawa, M., Maeda, M., Matoba, M., Ishii, T., Kuribayashi, R., Tenta, M., Matsushita, Y., et al. (2022) · doi:10.22541/au.165854349.92885870/v1
The evidence behind early aggressive multi-drug treatment in type 2 diabetes
Cersósimo, E., Solis‐Herrera, C., & Triplitt, C. L. (2021) · Trends in Diabetes and Metabolism · doi:10.15761/tdm.1000121
Review on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus
Mukhopadhyay, J. (2022) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2022.20.3.0371
Gliflozine e sindrome cardio-renale
Petralli, G., Biancalana, E., Piazza, G., & Solini, A. (2022) · il Diabete · doi:10.30682/ildia2203c
Uno scompenso per due, col terzo incomodo
Fadini, G. P. (2022) · il Diabete · doi:10.30682/ildia2203b
Cleary, D., Hannou, S., Quiaios, L., Monney, P. A., Hullin, R., Wojtusciszyn, A., Büla, C., & Nguyen, S. (2022) · JMIG · doi:10.53738/revmed.2022.18.802.2057
Sanz, F. V. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/2022.2/art5
Diabetic Kidney Disease: State of the Art
Calvo, C. D. P. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.16.002265
Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control
La Salle, J., Uusinarkaus, K., Family Medicine, C. P. C., Marso, S. P., Cardiovascular Medicine, H. M. H., & Pantalone, K. M. (2023) · Journal of Family Medicine · doi:10.26420/jfammed.2023.1325
Kaewpoomha, S., Bunman, S., & Wannapaschaiyong, P. (2023) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2023.11.003
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Krishnan, R., Subramanian, R., & Selvarajan, R. (2023) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20230320
(2022) · Journal of Obesity and Chronic Diseases · doi:10.17756/jocd.2022-050
Grassi, B. A., Hernández, C., Boncompte, M., Henríquez, C., Marinovic, N. L., Miranda, F., Papic, K. V., & Alfaro, V. R. (2022) · Revista médica de Chile · doi:10.4067/s0034-98872022001001334 · Cited by 1
Eriş, D. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2576
Overview about Correlation between Heart Failure and Diabetes Mellitus: Review Article
Mabrouk, A. R. R., Elmaghawry, L. M., Shereef, A. S., & El-Shetry, M. S. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.296743
Mechanisms of SGLT2 inhibition in the kidney
Sen, T. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.659987622
Chopra, H. K., Wande, G. S., Nair, T., Ponde, C. K., Nanda, N. C., Narula, J., Ray, S., Venugopal, K., Iyengar, S. S., Kasliwal, R. R., et al. (2023) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0230
Heeba, G. H., Abolnaga, M., & Othman, E. M. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.301257
Айтбаев, К. А., Murkamilov, I. T., Fomin, V. V., Абдилалимовна, М. Ж., Kudaibergenova, I., & Yusupov, F. A. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3457
SGLT2 inhibitors and cardioprotection. Literature review and real-world data from Poland
Seweryn, M., & Augustyńska, J. (2022) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2022.1.1
Nedogoda, S. V., Salasyuk, A. S., Barykina, I. N., Lutova, V. O., & Popova, E. A. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5475
Бояковская, Т. Г., & Горюнова, В. М. (2023) · ТЕНДЕНЦИИ РАЗВИТИЯ НАУКИ И ОБРАЗОВАНИЯ · doi:10.18411/trnio-06-2023-406
Tutillo, E. L. B., & Rosero, E. A. R. (2023) · MQRInvestigar · doi:10.56048/mqr20225.7.3.2023.1959-1978
A comparative study for GLP-1 levels in Iraqi diabetic patients with hyper & hypothyroidism
Al-Rubaei, Z. M., timari, U. S. A., & Alobaydi, H. A. (2018) · Al-Kufa University Journal for Biology · doi:10.36320/ajb/v10.i1.8205
Venda, J., & Leal, R. G. C. (2023) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2023.08.253
EFICÁCIA E SEGURANÇA DE NOVAS ABORDAGENS FARMACOLÓGICAS NO TRATAMENTO DA DIABETES TIPO 2
Pereira, A. C. S., Torres, L. M. C., Biasi, M. P., Scartazzini, M. V. S., Figueiredo, L. M., Côrtes, P. H., Ramos, R. C., da Silva, T. H., Brandão, P. A. D. V., & Cavalcante, I. F. D. M. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i7.10786
La progressione della malattia renale cronica
Manfellotto, D., & Pinna, G. (2023) · Italian Journal of Medicine · doi:10.4081/itjm.q.2023.3
Т.Л., М. (2023) · Український медичний часопис · doi:10.32471/umj.1680-3051.156.246246
Batista, P. E. M., Monges, A. E. A., & Baldissera, P. M. (2023) · Research Society and Development · doi:10.33448/rsd-v12i9.41542
SGLT2 inhibitors: a new weapon against aging?
Frigé, C. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.3.2
Canagliflozin produces a vasorelaxation effect on isolated rat thoracic aorta via NO/cGMP pathwaysPreprint
Tariq, M. S., Anjum, İ., Mushtaq, M. N., Barkat, K., Badshah, S. F., Ashraf, M. U., Malik, M. N. H., Jardan, Y. A. B., Nafidi, H., & Bourhia, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3508820/v1
Der Stoff aus der Apfelrinde im Kampf gegen Diabetes (Gliflozine)
Giannis, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-67510-6_7
¿Qué nos han demostrado los arGLP-1 en el abordaje integral temprano?
García, M. C. G., & Lachica, L. Á. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.manejointegral.art3
¿Por qué es necesaria la protección holística de la persona con diabetes mellitus tipo 2?
Bravo, J. J. M. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.proteccionholistica.art1
¿Cómo podemos realizar la protección renal del paciente con DM2?
Cuenca, A. M. C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.proteccionholistica.art4
Tratamiento y seguimiento de personas con diabetes mellitus y enfermedad renal crónica
Bravo, J. J. M. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art7
Gil, F. M. A. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.proteccionholistica.art3
¿Es importante identificar los factores de riesgo en los pacientes DM2?
Obaya, J. C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.proteccionholistica.art2
Perfil de seguridad y beneficios de los fármacos antidiabéticos en cuanto al riesgo cardiovascular
Dulcey, L., Therán, J. S., Cabrera, V., Parales, R., Caltagironne, R., Blanco, E., & Ciliberti, M. (2023) · Acta Bioclínica · doi:10.53766/acbio/2023.13.26.11
Celik, Y. (2023) · Mevlana Medical Sciences · doi:10.56752/mevmedsci.2023.42
Peran SGLT2i terhadap Risiko Kardiorenal Pasien dengan atau Tanpa Diabetes Melitus Tipe 2
Allen (2024) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v51i2.873
Vasconcelos, J. L. M., Pinto, A. D. C. P., Silva, A. E. S., Lima, A. L., Duarte, C. M., Almeida, C. E. D. C., Batista, C. D. B. P., Simsen, E. M., Roque, G. P., Pires, I. O., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n2p821-829
UPDATED MEDICINES FOR DIABETICS
al-nefaie, M. D., alotaibi, R. H., alotaibi, S. M., Alnafeiai, N. A., Alotaibi, M. A., Alotaibi, M. T., & Alamri, S. A. (2022) · doi:10.53555/jptcp.v29i03.4532
SGLT2 Inhibitors and Mechanisms of Arterial Hypertension
Raimzhanov, A. A., & Mangasaryan, A. A. (2023) · Texas Journal of Medical Science · doi:10.62480/tjms.2023.vol18.pp13-16
Saldanha, D., Santiago, L. M., Oliveiros, B., Pestana, J., & Topázio, U. (2024) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v40i1.13769
Gutierrez, M. R., Martins, J. P. B. C., Cavalcante, A. S. D. A., Silva, M. C. D. F., Magalhães, M. I. S., Assis, L. G. D. R., Augusto, É. M., Figueiredo, D. G. D. A., Valentim, C. G. Q., & Batocchio, G. T. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i3.13219
Madagam, S. (2024) · Urinary and Renal Research · doi:10.54517/urr.v5i1.2402
Liu, X., Wang, W., & Xing, X. (2024) · The Heart Surgery Forum · doi:10.59958/hsf.7021
", Павловна, М. А., As, A., Васильевна, К. Л., & Korotkova, T. N. (2024) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2024-13-1-7-15
Mori, T., Yano, T., Yoshioka, K., & Miyazaki, Y. (2024) · Signa Vitae · doi:10.22514/sv.2024.052
Dias, I. G., Silveira, R. M., Martins, G. C., Costa, P. P. T., & Pamplona, V. R. V. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i5.13819
Approche de la décision partagée concernant la prise en charge du diabète de type 2
MacDonald, B. J., McCormack, J. P., & Turgeon, R. D. (2024) · Canadian Family Physician · doi:10.46747/cfp.7005316
ABORDAGENS TERAPÊUTICAS PARA O CONTROLE DA DIABETES TIPO 2: UMA ANÁLISE COMPARATIVA
Breitenbach, L. M., Soares, L. D. L., Coelho, R. S., Júnior, L. R. D. A., Rodrigues, M. G. D. O., Viana, L. F., Soares, A. C. P., Miranda, L. A., Páiva, M. V. B. D. N., & Andrade, Q. D. C. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i6.14765
CAPÍTULO 6: INHIBIDORES DEL COTRANSPORTE SGLT-2
Inserra, F., Sanabria, H. D., Castaño, Y., Castellaro, C., Márquez, D. F., Dorado, E., & Sivak, L. (2024) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v58i2sup.789
Shamshuzoha, M., Chavan, P., & Thamburaj, J. (2024) · Indian Journal of Case Reports · doi:10.32677/ijcr.v10i7.4536
Comprehensive management of polypharmacy in older patients with diabetes
Park, K. S., & Yu, H. M. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.7.449
Spratt, M. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.250821
Manual de Medicina Interna Vol. 6
Verduga, M. D. F. N., Vélez, K. E. C., Guaman, J. D. R., Mendoza, H. N. G., Sánchez, L. M. C., Guajala, R. G. Y., & Vera, A. G. M. (2024) · doi:10.56470/978-9942-660-78-7
Devolder, M. E. C., Pereira, S. T., Pinto, R. F. M., Dourado, P. A. L., Rocha, D. R. B., Gomes, D. H. S., Urquizo, P. S. S., Cardoso, R. M., Dantas, L. C., & Klein, L. G. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i8.15327
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2
Combinações de Diuréticos: Fisiopatologia, Evidência e Prática Clínica
Mourilhe‐Rocha, R., Ribeiro, P. F., Sales, A. L. F., Spineti, P. P. D. M., Albuquerque, F. N., & Bittencourt, M. I. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240020
Diuretic Combinations: Pathophysiology, Evidence, and Clinical Practice
Mourilhe‐Rocha, R., Ribeiro, P. F., Sales, A. L. F., Spineti, P. P. D. M., Albuquerque, F. N., & Bittencourt, M. I. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240020i
Sagara, R., Sonoda, N., Ikeda, M., Tohyama, T., Nishizaka, M., Yamasaki, Y., Tagawa, K., Hamase, K., Nakashima, N., Ishigami, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5351010/v1
Bhadury, S., Das, K. K., & Chakrabarti, D. (2024) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-8056
Tecnológico de Monterrey Campus Monterrey, N. L., López, D. E. S., Hernández, E. A. V., Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, M., Mireles, A. A. E., Zacatecas, U. A. D. Z., López, O. A. R., Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, M., Castillo, C. L. H. M., Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, M., et al. (2024) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v4-i12-30
Zhang, Y., Liu, Y.-X., & Yang, W. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i1.100886
The role of SGLT2 inhibitors in protecting cardiovascular health: beyond glycaemic control
Alharbi, S. A., Alsubaiei, A. A., Alkhalifah, A. H., Alshehri, A. A., Alhaggas, S. S., Alhuthli, S. M., Alfaqih, Y. H., Alnajjar, W. Z., Alshaban, G. A., Ahmed, M. S., et al. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20250050
The Significance and Exploration of Opportunistic Screening in the Prevention of Heart Failure
柴, 程. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42289
Lei, Y., Liu, Y., Gao, L., Xu, P. H., Chen, L., Li, C., Chen, W., Xu, J., Ouyang, D., & Li, X. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1530
Advances in SGLT2 Inhibitors for Cardiovascular Diseases
员, 峰. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1592519
Li, W., Yang, Z., Wang, X., Guo, P., Wu, L., Wang, Y., Lyu, Y., Xu, X., & Ji, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1651847
Muir, K. C., Stone, C. R., & Sellke, F. W. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm46451
Dai, H., Lee, Y. A., Bian, J., & Guo, J. S. (2025) · medRxiv · doi:10.1101/2025.11.25.25341015
Chen, J., Chang, J., Shi, Q., Li, X., Wang, L., & Zhao, H. (2023) · Figshare · doi:10.6084/m9.figshare.24266039
Pang, C., Zhang, W., Yue, C., Li, H., Li, J., Wang, X., Duan, X., Li, L., Gao, Z., & Hai, X. (2026) · Journal of Toxicology · doi:10.1155/jt/5808911
Pan, M., Wang, P., Wang, X., Wang, Z., Zhang, Z., Yang, K., Liu, W., Ma, W., & Liu, X. B. (2026) · Medicine · doi:10.1097/md.0000000000047533
Rôle des péricytes et des cellules endothéliales dans l'insuffisance cardiaque
Cornuault, L. (2022) · theses.fr (ABES) · doi:10.70675/902151b1zd809z4b09z9562zd16a859cc3f2
Gerges, Z., Ramkumar, A., Hossain, M. I., & Tee, S. S. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00284-6
Kim, S., Cho, M. S., Park, S.-Y., Choi, Y., Lee, J., Park, D. W., Nam, G., & Oh, Y. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047672
Teng, J., Li, T., Tan, Y., & Tang, H. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1775359
Jiao, Y., & Ma, J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54062
Sagan, D., Góral, M., Siedlecki, R., Fidorowicz, D., Sergiel, K. H., Torbacka, E., Skuza, A. I., Downar-Zapolska, M., Mikłaszewicz, A., & Bednarczuk, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5476
Lv, Z., Yu, J., Bian, D., Yao, S., Zhang, J., & 郭登洲 (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122138
Salgado, T. M., Amayreh, R., Alshahawey, M., Musselman, K. T., Buffington, T. M., Hyder, H., Jones, R. M., & Dixon, D. L. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70263
Mohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70298
Tong, Y., Wang, C., Sun, Y., Zhang, X., Fang, H., Xie, Y., Xiao, Y., Ma, S., Li, W., & Wang, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1931102
Metadata
- Authors
- Sarafidis, P. A., & Τσάπας, Α.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-17
- Volume
- 374
- Issue
- 11
- Pages
- 1092-1094
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2297835124
- Cited by
- 700
- References
- 9
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
- MeSH terms
- Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
